Utility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling-Reference-Cited by-同舟云学术

Utility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling

Published:2017-03-04 Issue:2 Volume:17 Page:153-164
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Brown Jacqueline¹,Cook Keziah²,Adamski Kelly²,Lau Jocelyn²,Bargo Danielle³,Breen Sarah³,Chawla Anita²

Affiliation:

1. Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Windlesham, UK

2. Analysis Group, Inc, Menlo Park, CA, USA

3. UK Health Outcomes and HTA team, Eli Lilly and Company Limited, Basingstoke, Hampshire, UK

Funder

Eli Lilly and company

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2017.1311210

Reference47 articles.

1. Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report

2. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. [cited 2015 October 8]; Available from: http://publications.nice.org.uk/pmg9.

3. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

4. EuroQol - a new facility for the measurement of health-related quality of life

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of loneliness and social isolation on health state utility values: a systematic literature review;Quality of Life Research;2022-01-24

2. Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis;Frontiers in Oncology;2021-03-25

3. Cost‐effectiveness analysis of first‐line treatments for advanced epidermal growth factor receptor‐mutant non‐small cell lung cancer patients;Cancer Medicine;2021-02-24

4. A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer;PharmacoEconomics - Open;2021-01-19

5. Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer;Chinese Medical Journal;2020-09-30